Jump to content

KRAS. Help on the way?


Recommended Posts

Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target [1]. In presenting positive data from a Phase I dose-escalation study of AMG 510, an oral small molecule inhibitor of KRAS G12C. AMG 510 achieved a 50% response rate among non-small cell lung cancer (NSCLC) patients expressing the KRAS G12C mutation.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.